Pfizer Inc. (NYSE: PFE) today announced that REFLECTIONS B3281006, a comparative safety and efficacy study of PF-05280586 versus MabThera® (rituximab-EU) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

'Steady Bullish' Options Activity in Pfizer (PFE) Ahead of Q4 Earnings Announcement on Jan. 30th -Susquehanna January 26, 2018 2:39 PM Pfizer Announces Positive Top-Line Results For Potential Biosimilar To Rituxan®/MabThera®January 24, 2018 8:30 AM